Compare LCTX & SPIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCTX | SPIR |
|---|---|---|
| Founded | 1990 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Telecommunications Equipment |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 407.7M | 347.1M |
| IPO Year | N/A | N/A |
| Metric | LCTX | SPIR |
|---|---|---|
| Price | $1.67 | $7.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $4.25 | ★ $11.63 |
| AVG Volume (30 Days) | ★ 1.2M | 782.6K |
| Earning Date | 11-06-2025 | 12-17-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ 0.81 |
| Revenue | $10,816,000.00 | ★ $77,387,000.00 |
| Revenue This Year | $6.32 | N/A |
| Revenue Next Year | $124.49 | $9.87 |
| P/E Ratio | ★ N/A | $9.36 |
| Revenue Growth | ★ 24.05 | N/A |
| 52 Week Low | $0.37 | $6.60 |
| 52 Week High | $2.09 | $21.43 |
| Indicator | LCTX | SPIR |
|---|---|---|
| Relative Strength Index (RSI) | 46.04 | 40.65 |
| Support Level | $1.58 | $7.52 |
| Resistance Level | $1.77 | $9.53 |
| Average True Range (ATR) | 0.08 | 0.67 |
| MACD | -0.01 | -0.09 |
| Stochastic Oscillator | 32.65 | 22.70 |
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.
Spire Global Inc is a provider of space-based data, analytics, and Space Services, offering datasets and powerful insights about Earth from the ultimate vantage point of space so that organizations can make decisions with confidence, accuracy, and speed. It generates revenue from four solutions: Maritime, Aviation, Weather, and Space Services. It offers the following three data solutions to customers; Maritime-precise space-based data used for accurate ship monitoring, ship safety, and route optimization, Aviation-precise space-based data used for accurate aircraft monitoring, aircraft safety, and route optimization, and Weather-precise space-based data used for accurate weather forecasting.